Related Experiment Video
Updated: Jul 13, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
Spotlight on quetiapine in bipolar depression
Gillian M Keating1, Dean M Robinson
1Wolters Kluwer Health/Adis, Auckland, New Zealand. demail@adis.co.nz
Quetiapine monotherapy effectively treats bipolar depression, improving mood and anxiety symptoms without increasing mania risk. This atypical antipsychotic offers a well-tolerated, first-line option for acute bipolar depression management.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Quetiapine is the sole atypical antipsychotic approved in the US for monotherapy in bipolar mania and depression.
- This offers potential advantages for patient compliance.
Purpose of the Study:
- To evaluate the efficacy and tolerability of quetiapine monotherapy in treating bipolar depression.
Main Methods:
- Oral quetiapine at 300 mg/day was administered to patients with bipolar I or II depression.
Main Results:
- Quetiapine monotherapy demonstrated effectiveness in treating bipolar depression.
- Rapid and sustained improvements were observed in depressive and anxiety symptoms.
- Health-related quality of life also improved with quetiapine treatment.
- The drug was generally well tolerated and did not increase the risk of treatment-emergent mania.
Conclusions:
- Quetiapine monotherapy is an effective treatment for acute bipolar depression.
- It offers rapid, sustained symptom improvement and is well-tolerated.
- Considered a first-line option for bipolar depression despite limited active comparator data.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Mania and Antimanic Drugs: Overview
Bipolar Disorder
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Overview
Psychosis and Antipsychotic Drugs: Overview